In summary, we propose that levels of JUN and STAT3 potentially orchestrated via PTEN, determine progression stages of human prostate tumors by modulating the immune response through regulation of cytokines and interleukins as identified in the Jun-deficient murine PCa model. Here, JUN is linked to prostate neoplasm.